According to the editors of Sciencedaily,A group of neuroscientists from Georgetown University Medical Center has developed and even successfully tested a drug that reduces the accumulation of toxic proteins and other decay products. Thus, it is possible to achieve the prevention and treatment of neurodegenerative conditions like Parkinson's and Alzheimer's diseases, as well as rehabilitation after impaired motor function due to stroke.
October 22 at the international conference of the SocietyChicago-based neuroscientists have presented test results for a substance codenamed CM101. Compound CM101 stimulates the elimination of damaged folded proteins and toxic products from the brain. Among which there are alpha-synucleins, tau and beta-amyloids, responsible for the development of a number of neurodegenerative processes in the central nervous system.
Very low dose CM101 enhances excretionproteins from brain neurons for several hours. This is just enough to ensure the removal of neurotoxic proteins from cells and intercellular space, ”says Charbel Mussa, Ph.D., leading author and associate professor of neurology, Georgetown University.
The current work is a continuationstudies by scientists on how agents known as tyrosine kinase inhibitors can enhance protein removal and potentially stop neurodegenerative diseases. Previous work led experts to clinical trials of two anti-cancer drugs that are tyrosine kinase (TCS) inhibitors - Nilotinib and Bosutinib. These two drugs are prescribed to patients for the treatment of leukemia in doses that are 10 times higher than what is needed to start cleaning from the accumulation of protein in neurons.
In the study of drugs and theireffects on metabolic processes, the researchers found that 2 of the above drugs inhibit a number of different brain tyrosine kinases, which enhances the elimination of toxic products. A leading role in this process is played by a number of molecules, which scientists synthesized and received CM101.
We are redesigning cancer treatmentsin order to help people get rid of neurodegenerative disorders. Our studies show that this strategy works even in neurons that are affected, but have not yet died under the influence of toxins.
CM101, according to scientists, has passed extensivetests in several series of tests on laboratory animals that have artificially caused neurodegenerative diseases. In most cases, it was possible to achieve maximum protein excretion and improve brain function. Animals also improved coordination and memory. By the way, we constantly report on the success of this kind of research, so we recommend subscribing to our channel in Telegram in order to be in the know.
See also: Scientists have found a region of the brain in which Alzheimer's disease originates
The next step in the work is research.toxicity of the drug, as well as the identification of its side effects. The possibility of the effect of the drug on other organs and tissues, in particular on the bone marrow and hematopoietic system, cannot be ruled out, since the drug has “anti-oncological roots”. Once the safety of the CM101 is proven, a large-scale trial of the new drug in humans will begin.